In Vitro Pharmacokinetics of LL-37 and Oncorhyncin II Combination Against Acinetobacter baumannii

Background: Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most common nosocomial pathogens. Antimicrobial peptides (AMPs) have been introduced as a viable alternative to antibiotics in treatment MDR Objectives: This study was designed assess vitro pharmacokinetics combination two potent AMPs, LL-37 and oncorhyncin II, against A. (ATCC19606). Methods: The synthesized genes II were into Escherichia coli BL21 expression host. minimum inhibitory concentration (MIC), time-kills, growth kinetics these used evaluate their antimicrobial efficiencies Results: recombinant showed MIC 30.6 95.87 µg/mL baumannii, respectively. Additive action confirmed by combining generated AMPs at checkerboard approach. 2 × resulted rapid drop log10 CFU/mL time-kill kinetic findings studies. Conclusions: produced synergizes bioactivity individual peptides. Therefore, or combinations might function novel be develop produce new drugs for infections caused baumannii.